Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.

Lung cancer (Amsterdam, Netherlands) - 1 Sept 2016

Eng Juliana, Hsu Meier, Chaft Jamie E, Kris Mark G, Arcila Maria E, Li Bob T

Abstract excerpt

Human epidermal growth factor receptor 2 (HER2, ERBB2) mutations occur in 3% of lung adenocarcinomas. While case reports and series have shown activity of HER2 targeted agents in these patients, little is known about outcomes of chemotherapies. Patients with stage IV HER2-mutant lung cancers at Memorial Sloan Kettering were reviewed. Patient demographics, types of HER2 mutations, duration of systemic treatments...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Neoplasm Staging

Share to Receptor, ErbB-2

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 27565914
DOI: 10.1016/j.lungcan.2016.05.030
PMCID: PMC5305295

Genes

ERBB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.PMID 27565914Read ↗

Lung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic PerspectivesSemantic proximity Read ↗

HER2-Mutant Advanced and/or Metastatic Non-Small-Cell Lung Cancer: A US Electronic Health Records Database Analysis of Clinical Characteristics, Treatment Practice Patterns, and Outcomes.Semantic proximity Read ↗

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers.Semantic proximity Read ↗

Treatment Outcome and Clinical Characteristics of HER2 Mutated Advanced Non-Small Cell Lung Cancer Patients in ChinaSemantic proximity Read ↗

Real-World Patient Characteristics, Mutational Landscape, and Outcomes in Advanced/Metastatic HER2-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.Semantic proximity Read ↗

Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.Semantic proximity Read ↗

Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China.Semantic proximity Read ↗

Clinical Efficacy of HER2-targeted Monotherapy in ERBB2-mutant Non-Small-Cell Lung Cancer: A Systematic Review and Single-arm Meta-Analysis.Semantic proximity Read ↗

Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial.Semantic proximity Read ↗

Real-world therapeutic strategies and survival outcomes in advanced HER2 -mutant non-small cell lung cancer.Semantic proximity Read ↗

Real-world clinical characteristics and outcomes in patients with HER2-mutant non-small cell lung cancer (NSCLC) who received second-line treatment: A nationwide database analysis in Japan.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.